Literature DB >> 8878152

Polyunsaturated fatty acid deficiency in liver diseases: pathophysiological and clinical significance.

E Cabré1, M A Gassull.   

Abstract

Polyunsaturated fatty acid (PUFA) deficiency occurs in advanced cirrhosis and other liver diseases (acute hepatitis, cholestasis). Long-chain PUFA deficit in cirrhosis is due to both essential fatty-acid (EFA) deficiency and impaired PUFA biosynthesis. Although hepatic insufficiency itself mostly accounts for this phenomenon, other factors such as associated malnutrition also play a role. PUFA deficiency in cirrhosis probably has a wide array of both cellular and clinical consequences, but, at present, they have been difficult to prove. In addition, the route, dosage, and safety of PUFA supplementation in these patients needs extensive investigation in the future.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878152     DOI: 10.1016/s0899-9007(96)00122-0

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  9 in total

1.  Supplementation of arachidonic acid plus docosahexaenoic acid in cirrhotic patients awaiting liver transplantation: a preliminary study.

Authors:  Sassan Pazirandeh; Pei-Ra Ling; Mario Ollero; Fredric Gordon; David L Burns; Bruce R Bistrian
Journal:  JPEN J Parenter Enteral Nutr       Date:  2007 Nov-Dec       Impact factor: 4.016

2.  Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice.

Authors:  Rachel M Golonka; Beng San Yeoh; Yaqi Li; Piu Saha; Ahmed A Abokor; Xi Cheng; Xia Xiao; Darshan Shimoga Chandrashekar; Sooryanarayana Varambally; David J Gonzalez; A Catharine Ross; Matam Vijay-Kumar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-03-23       Impact factor: 4.052

3.  Reduced brain content of arachidonic acid and docosahexaenoic acid is related to the severity of liver fibrosis.

Authors:  Chih-Cheng Chen; Li-Tung Huang; You-Lin Tain; Hsio-Chi Chaung; Chih-Sung Hsieh; Hock-Liew Eng; Yu-Ching Wei; Chun-Yu Yang
Journal:  Dig Dis Sci       Date:  2010-01-26       Impact factor: 3.199

Review 4.  Current therapies in alleviating liver disorders and cancers with a special focus on the potential of vitamin D.

Authors:  Shahida Khan; Ashraf Ali; Sarah Khan; Ahmed Bakillah; Ghazi Damanhouri; Aziz Khan; Ahmad Makki; Ibtehal AlAnsari; Naheed Banu
Journal:  Nutr Metab (Lond)       Date:  2018-02-09       Impact factor: 4.169

5.  Metabolomic serum abnormalities in dogs with hepatopathies.

Authors:  Carolin A Imbery; Frank Dieterle; Claudia Ottka; Corinna Weber; Götz Schlotterbeck; Elisabeth Müller; Hannes Lohi; Urs Giger
Journal:  Sci Rep       Date:  2022-03-29       Impact factor: 4.379

6.  Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.

Authors:  Edana Cassol; Vikas Misra; Alexander Holman; Anupa Kamat; Susan Morgello; Dana Gabuzda
Journal:  BMC Infect Dis       Date:  2013-05-04       Impact factor: 3.090

7.  Abnormalities in the serum phospholipids fatty acid profile in patients with alcoholic liver cirrhosis - a pilot study.

Authors:  Danijela Ristić-Medić; Marija Takić; Vesna Vučić; Dragoslav Kandić; Nada Kostić; Marija Glibetić
Journal:  J Clin Biochem Nutr       Date:  2013-06-07       Impact factor: 3.114

Review 8.  Nutrition in Chronic Liver Disease.

Authors:  Marco Silva; Sara Gomes; Armando Peixoto; Paulo Torres-Ramalho; Hélder Cardoso; Rosa Azevedo; Carla Cunha; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2015-08-31

9.  Liver Lipids of Patients with Hepatitis B and C and Associated Hepatocellular Carcinoma.

Authors:  Elisabeth M Haberl; Thomas S Weiss; Georg Peschel; Kilian Weigand; Nikolai Köhler; Josch K Pauling; Jürgen J Wenzel; Marcus Höring; Sabrina Krautbauer; Gerhard Liebisch; Christa Buechler
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.